Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006

K Smyth, J S Affandi, J C McArthur, C Bowtell-Harris, Anne M Mijch, K Watson, K Costello, Ian J Woolley, P Price, Steven Lodewyk Wesselingh, Catherine Cherry

Research output: Contribution to journalArticleResearchpeer-review

89 Citations (Scopus)

Abstract

OBJECTIVES: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre-HAART) and 2001 (frequent use of dNRTI-containing HAART). METHODS: This was a cross-sectional comparative study using convenience sampling. HIV-positive adults attending a tertiary referral clinic over a 2-week period were screened for HIV-SN using the AIDS Clinical Trials Group screening tool. HIV-SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV-SN, and results were compared with data obtained in the same clinic in 1993 and 2001. RESULTS: One hundred patients were screened. The prevalence of HIV-SN was 42 , which was unchanged since 2001 (44 ) despite a significant reduction in the use of dNRTIs. HIV-SN remained much more common than in 1993 (42 vs 13 ; P
Original languageEnglish
Pages (from-to)367 - 373
Number of pages7
JournalHIV Medicine
Volume8
Issue number6
DOIs
Publication statusPublished - 2007

Cite this

Smyth, K ; Affandi, J S ; McArthur, J C ; Bowtell-Harris, C ; Mijch, Anne M ; Watson, K ; Costello, K ; Woolley, Ian J ; Price, P ; Wesselingh, Steven Lodewyk ; Cherry, Catherine. / Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. In: HIV Medicine. 2007 ; Vol. 8, No. 6. pp. 367 - 373.
@article{b3d2fad210eb497092558708131adc10,
title = "Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006",
abstract = "OBJECTIVES: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre-HAART) and 2001 (frequent use of dNRTI-containing HAART). METHODS: This was a cross-sectional comparative study using convenience sampling. HIV-positive adults attending a tertiary referral clinic over a 2-week period were screened for HIV-SN using the AIDS Clinical Trials Group screening tool. HIV-SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV-SN, and results were compared with data obtained in the same clinic in 1993 and 2001. RESULTS: One hundred patients were screened. The prevalence of HIV-SN was 42 , which was unchanged since 2001 (44 ) despite a significant reduction in the use of dNRTIs. HIV-SN remained much more common than in 1993 (42 vs 13 ; P",
author = "K Smyth and Affandi, {J S} and McArthur, {J C} and C Bowtell-Harris and Mijch, {Anne M} and K Watson and K Costello and Woolley, {Ian J} and P Price and Wesselingh, {Steven Lodewyk} and Catherine Cherry",
year = "2007",
doi = "10.1111{\%}2Fj.1468-1293.2007.00478.x",
language = "English",
volume = "8",
pages = "367 -- 373",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "6",

}

Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. / Smyth, K; Affandi, J S; McArthur, J C; Bowtell-Harris, C; Mijch, Anne M; Watson, K; Costello, K; Woolley, Ian J; Price, P; Wesselingh, Steven Lodewyk; Cherry, Catherine.

In: HIV Medicine, Vol. 8, No. 6, 2007, p. 367 - 373.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006

AU - Smyth, K

AU - Affandi, J S

AU - McArthur, J C

AU - Bowtell-Harris, C

AU - Mijch, Anne M

AU - Watson, K

AU - Costello, K

AU - Woolley, Ian J

AU - Price, P

AU - Wesselingh, Steven Lodewyk

AU - Cherry, Catherine

PY - 2007

Y1 - 2007

N2 - OBJECTIVES: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre-HAART) and 2001 (frequent use of dNRTI-containing HAART). METHODS: This was a cross-sectional comparative study using convenience sampling. HIV-positive adults attending a tertiary referral clinic over a 2-week period were screened for HIV-SN using the AIDS Clinical Trials Group screening tool. HIV-SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV-SN, and results were compared with data obtained in the same clinic in 1993 and 2001. RESULTS: One hundred patients were screened. The prevalence of HIV-SN was 42 , which was unchanged since 2001 (44 ) despite a significant reduction in the use of dNRTIs. HIV-SN remained much more common than in 1993 (42 vs 13 ; P

AB - OBJECTIVES: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre-HAART) and 2001 (frequent use of dNRTI-containing HAART). METHODS: This was a cross-sectional comparative study using convenience sampling. HIV-positive adults attending a tertiary referral clinic over a 2-week period were screened for HIV-SN using the AIDS Clinical Trials Group screening tool. HIV-SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV-SN, and results were compared with data obtained in the same clinic in 1993 and 2001. RESULTS: One hundred patients were screened. The prevalence of HIV-SN was 42 , which was unchanged since 2001 (44 ) despite a significant reduction in the use of dNRTIs. HIV-SN remained much more common than in 1993 (42 vs 13 ; P

UR - http://www.blackwell-synergy.com/action/showPdf?submitPDF=Full+Text+PDF+%2894+KB%29&doi=10.1111%2Fj.1468-1293.2007.00478.x

U2 - 10.1111%2Fj.1468-1293.2007.00478.x

DO - 10.1111%2Fj.1468-1293.2007.00478.x

M3 - Article

VL - 8

SP - 367

EP - 373

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 6

ER -